Adjuvant diagnosis of tuberculosis in hemodialysis patients using fourth generation interferon γ releasing assay. Issue 3 (17th October 2022)

• Record Type: Journal Article
• Authors: Chinen, Miria; Katagiri, Daisuke; Sakamoto, Emi; Noguchi, Haruka; Suzuki, Mikako; Kondo, Isao; Niikura, Takahito; Arai, Yohei; Suzuki, Minami; Hinoshita, Fumihiko; Takano, Hideki
• Is Part Of: Therapeutic apheresis and dialysis. Volume 27:Issue 3(2023)
• Page Start: 435
• Page End: 441
• Publication Date: 2022-10-17
• Subjects: dialysis -- interferon γ releasing assay -- latent tuberculosis infection -- tuberculosis; Hemapheresis -- Periodicals; Dialysis -- Periodicals; Blood Component Removal -- Periodicals; Renal Dialysis -- Periodicals; Hémaphérèse -- Périodiques; Dialyse -- Périodiques; Sang -- Collecte et conservation -- Périodiques; 616
• DOI: 10.1111/1744-9987.13939
• Languages: English
• ISSNs: 1744-9979

Abstract

Abstract: Introduction: Dialysis patients have a 10–25 times higher risk of reactivation of tuberculosis (TB). In this study, we investigated the diagnostic ability of QuantiFERON (QFT)‐plus for TB in hemodialysis patients. QFT‐plus, an interferon gamma release assay, is characterized by its use of CD4 and CD8 T cell signals. Methods: Hemodialysis patients aged 20 years or older who underwent QFT‐plus measurement in our hospital were included, inclusion criteria being fever above 37°C, high inflammatory response, and infiltrative pulmonary shadows. Results: Forty‐six patients were enrolled. Of these, 15% were QFT positive, 4% were diagnosed with active TB, 76% were QFT negative, 8% had inconclusive results. Sensitivity, specificity, positive predictive value, and negative predictive value were 100%, 87.5%, 28%, and 100%, respectively. Conclusions: QFT‐plus may be useful for the diagnosis of active TB in dialysis patients. Further studies in cohorts with larger sample sizes are expected.